Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06251947
Other study ID # Guard-05
Secondary ID Guard-05
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 15, 2024
Est. completion date December 2026

Study information

Verified date May 2024
Source Shandong University
Contact Limei Wang
Phone 18560081708
Email 18560081708@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).


Description:

This study is a single-arm, multicenter clinical trial. A total of 83 patients will be enrolled, including 55 patients with primary epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) and 28 patients with primary or recurrent/metastatic cervical cancer in the first-line setting. 1) Ovarian Cancer Chemotherapy regimen (Paclitaxel + Carboplatin ± Bevacizumab): Paclitaxel 175mg/m2, intravenous infusion over 3 hours, on day 1; followed by Carboplatin Area under the curve 5(AUC5), intravenous infusion over 1 hour, on day 1; Bevacizumab 7.5-15 mg/kg, on day 1, administered as intravenous infusion; repeated every 3 weeks. (2) Cervical Cancer Chemotherapy regimen (Paclitaxel + Carboplatin/Cisplatin ± Bevacizumab): Paclitaxel 175mg/m2, intravenous infusion over 3 hours, on day 1; followed by Carboplatin AUC5, intravenous infusion over 1 hour, on day 1, or Cisplatin 50-80mg/m2, intravenous infusion over 1-3 hours, on day 1; Bevacizumab 7.5-15 mg/kg, on day 1, administered as intravenous infusion; repeated every 3 weeks. Efbemalenograstim Alfa should be administered subcutaneously, 20mg per injection, within 24-48 hours after the completion of each chemotherapy cycle.


Recruitment information / eligibility

Status Recruiting
Enrollment 83
Est. completion date December 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. = 18 years old and = 70 years old. 2. First-line epithelial ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) and first-line treatment or recurrent/metastatic cervical cancer. 3. Planned to receive 3-6 cycles of paclitaxel + carboplatin/cisplatin ± bevacizumab therapy. 4. Eastern Cooperative Oncology Group (ECOG) score < 2. 5. Expected survival time > 3 months. 6. Before enrollment, neutrophil count (ANC) = 2.0 × 10^9/L, hemoglobin (Hb) = 90.0 g/L, and platelet (PLT) = 80 × 10^9/L. 7. Associated with = 1 self-factors increasing the risk of febrile neutropenia (FN): ? age > 65 years, receiving full-dose intensity chemotherapy; ? history of previous chemotherapy or radiotherapy; ? persistent neutropenia; ? tumor involvement of the bone marrow; ? recent surgery and/or open wounds; ? hepatic dysfunction (bilirubin > 2.0 mg•dL-1); ? renal dysfunction (creatinine clearance rate < 50 mL•min-1); ? history of previous FN occurrence; ? concomitant malignant hematological or lymphatic system diseases; ? chronic immunosuppression; ? poor nutritional/physical status. Individualized judgment and decision-making based on the patient's specific condition are required in clinical practice. 8. Left ventricular ejection fraction (LVEF) > 50%. 9. Women who are not capable of reproduction, i.e., postmenopausal for at least 1 year or have undergone sterilization procedures (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy). Fertile patients agree to use appropriate contraceptive measures within 1 month before the start of the trial and up to 30 days after the end of the study, such as condoms, spermicidal condoms, foam, gel, diaphragm, intrauterine device (IUD), contraceptive pills (oral or injectable), etc. 10. Willing to provide written informed consent and to compliant study procedure. 11. The investigator determines that the patient can tolerate treatment with Efgbemalenograstim alfa. Exclusion Criteria: 1. Uncontrolled infection or systemic antibiotic therapy within 72 hours prior to chemotherapy. 2. Pregnant or lactating women. 3. History of bone marrow or stem cell transplantation. 4. Concurrent malignancies other than primary ovarian or cervical cancer. 5. Treatment with recombinant human granulocyte colony-stimulating factor within 6 weeks prior to enrollment. 6. Psychiatric illness or brain metastases. 7. Clinical, electrocardiographic, or other diagnostic evidence of acute congestive heart failure, cardiomyopathy, or myocardial infarction. 8. Diseases associated with splenomegaly. 9. Diagnosis of acute infection, chronic active hepatitis B within 1 year (unless known negative for hepatitis B virus antigen prior to enrollment), or hepatitis C. 10. Allergy to recombinant human granulocyte colony-stimulating factor or excipients of the study drug, or allergy to rubber. 11. Known positive serum reaction for human immunodeficiency virus (HIV) or AIDS. 12. Active tuberculosis or recent history of contact with a tuberculosis patient unless negative on tuberculin skin test, or receiving treatment for tuberculosis, or suspected case on chest X-ray examination. 13. Sickle cell anemia patients. 14. Use of other investigational drugs within 1 month prior to enrollment. 15. Patients who abuse alcohol or drugs, affecting their compliance with the study. 16. The investigator believes that the patient has a disease or symptom that makes them unsuitable for participation in this study, or that the study drug may harm the patient's health or affect the assessment of adverse events.

Study Design


Intervention

Drug:
Efbemalenograstim Alfa
Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Locations

Country Name City State
China Xiangya Hospital, Central South University, Changsha Hunan
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China Qilu Hospital of Shandong University Jinan Shandong
China Zhongda Hospital, School of Medicine, Southeast University Nanjing Jiangsu
China Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao Shandong
China Shanxi Provincial Cancer Hospital Taiyuan Shanxi

Sponsors (2)

Lead Sponsor Collaborator
Shandong University Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of grade 3/4 neutropenia Incidence of grade 3/4 neutropenia during the first chemotherapy cycle for participants receiving primary prophylaxis with Efgbemalenograstim alfa in the first treatment cycle At the first of cycle 1 (each cycle is 21 days)
Secondary The incidence rate of Grade 3/4 ANC reduction for each cycle The incidence rate of Grade 3/4 ANC reduction in every treatment cycle in every treatment cycle( each cycle is 21 days)
Secondary The incidence rate of Grade =2 ANC reduction for each cycle The incidence rate of Grade =2 ANC reduction in every treatment cycle in every treatment cycle( each cycle is 21 days)
Secondary The incidence rate of FN The incidence rate of febrile neutropenia (FN) for each cycle in every treatment cycle( each cycle is 21 days)
Secondary Adverse Events Including adverse events/serious adverse events and their incidence rates in every treatment cycle( each cycle is 21 days)
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2